Telomir Pharmaceuticals (TELO) Net Cash Flow (2023 - 2025)
Telomir Pharmaceuticals (TELO) posted Net Cash Flow of -$41281.0 for Q4 2025, down 100.63% sequentially from $6.6 million in Q3 2025, and down 109.57% YoY from $431493.0 in Q4 2024.
Telomir Pharmaceuticals (TELO) Net Cash Flow (2023 - 2025) Analysis & Trends
Telomir Pharmaceuticals has reported Net Cash Flow for 3 years, with the latest figure at -$41281.0 in Q4 2025.
- Quarterly Net Cash Flow fell 109.57% year-over-year to -$41281.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (up 292.2% YoY) and the FY2025 annual result came in at $6.0 million, up 375.04% from the prior year.
- Net Cash Flow fell to -$41281.0 in Q4 2025 per TELO's latest filing, from $6.6 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $6.6 million in Q3 2025 and troughed at -$1.4 million in Q2 2024.
- A 3-year average of $518805.8 and a median of -$6699.0 in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 843478.09% in 2024, down 10943.9% in 2024.
- Over 3 years, Net Cash Flow stood at -$1221.0 in 2023, then jumped by 35439.31% to $431493.0 in 2024, then tumbled by 109.57% to -$41281.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$41281.0, $6.6 million, and -$700000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41,281.00 |
| Dec 31, 2025 | -41,281.00 |
| Sep 30, 2025 | 6.60 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | -700,000.00 |
| Jun 30, 2025 | -700,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | 431,493.00 |
| Dec 31, 2024 | 431,493.00 |
| Sep 30, 2024 | -1.05 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | -1.39 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | -1,221.00 |
| Dec 31, 2023 | -1,221.00 |
| Sep 30, 2023 | -12,177.00 |
| Sep 30, 2023 | -12,177.00 |